Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease

被引：0
|
作者：
Jankovic, J.
Goodman, I.
Safirstein, B.
Schenk, D.
Kinney, G.
Koller, M.
Ness, D.
Griffith, S.
Grundman, M.
Soto, J.
Ostrowitzki, S.
Boess, F.
Martin-Facklam, M.
Quinn, J.
Isaacson, S.
Jennings, D.
Omidvar, O.
Ellenbogen, A.
机构：
来源：
MOVEMENT DISORDERS | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1418
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Results from a phase 1b multiple ascending-dose study of PRX002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's Disease
    Jankovic, J.
    Goodman, I.
    Safirstein, B.
    Schenk, D. B.
    Kinney, G. G.
    Koller, M.
    Ness, D. K.
    Griffith, S. G.
    Grundman, M.
    Soto, J.
    Ostrowitzki, S.
    Boess, F. G.
    Martin-Facklam, M.
    Quinn, J. F.
    Isaacson, S. H.
    Jennings, D.
    Omidvar, O.
    Ellenbogen, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 121 - 121
  • [2] RESULTS FROM A PHASE 1B MULTIPLE ASCENDING-DOSE STUDY OF PRX002/RG7935, AN ANTI-ALPHA-SYNUCLEIN MONOCLONAL ANTIBODY, IN PATIENTS WITH PARKINSON'S DISEASE
    Jankovic, J.
    Goodman, I.
    Safirstein, B.
    Schenk, D. B.
    Kinney, G. G.
    Koller, M.
    Ness, D. K.
    Griffith, S. G.
    Grundman, M.
    Soto, J.
    Ostrowitzki, S.
    Boess, F. G.
    Martin-Facklam, M.
    Quinn, J. F.
    Issacson, S. H.
    Jennings, D.
    Omidvar, O.
    Ellenbogen, A.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E25 - E25
  • [3] Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
    Jankovic, Joseph
    Goodman, Ira
    Safirstein, Beth
    Marmon, Tonya K.
    Schenk, Dale B.
    Koller, Martin
    Zago, Wagner
    Ness, Daniel K.
    Griffith, Sue G.
    Grundman, Michael
    Soto, Jay
    Ostrowitzki, Susanne
    Boess, Frank G.
    Martin-Facklam, Meret
    Quinn, Joseph F.
    Isaacson, Stuart H.
    Omidvar, Omid
    Ellenbogen, Aaron
    Kinney, Gene G.
    JAMA NEUROLOGY, 2018, 75 (10) : 1206 - 1214
  • [4] Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson's Disease
    Brys, Miroslaw
    Ellenbogen, Aaron
    Fanning, Laura
    Penner, Natasha
    Yang, Minhua
    Welch, Mackenzie
    Koenig, Erica
    David, Eric
    Fox, Tara
    Makh, Shavy
    Aldred, Jason
    Goodman, Ira
    Graham, Danielle
    Weihofen, Andreas
    Cedarbaum, Jesse
    NEUROLOGY, 2018, 90
  • [5] Baseline Characteristics of Participants of the SPARK Trial, a Phase 2 Study of the anti-alpha-synuclein antibody Cinpanemab (BIIB054) in Parkinson's Disease
    Fox, Tara
    Siderowf, Andrew D.
    Fernandez, Hubert H.
    Tanner, Caroline M.
    Postuma, Ronald B.
    Simon, David K.
    Byrne, Michael
    Lang, Anthony E.
    Brooks, David
    Rascol, Olivier
    Tolosa, Eduardo
    Poewe, Werner
    Stocchi, Fabrizio
    Mollenhauer, Brit
    Giladi, Nir
    Hirschhorn, Beth
    Cedarbaum, Jesse M.
    Nomikos, George
    Fanning, Laura
    Yang, Minhua
    Xiao, James
    Brys, Miroslaw
    NEUROLOGY, 2020, 94 (15)
  • [6] Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study)
    Levine, H. Terry
    Tauber, Joseph
    Nguyen, Quan
    Anesi, Stephen
    Chang, Peter
    Berdy, Gregg
    Lin, Charles
    Chu, David
    Kantor, Andrea
    Rasmussen, Henrik
    Singh, Bhupinder
    Chang, Alan
    Jeng, Bennie
    Jhanji, Vishal
    Foster, C. Stephen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB185 - AB185
  • [7] Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
    Kalluri, H.
    Zadikoff, C.
    Rueter, L.
    Graff, O.
    Xiong, H.
    MOVEMENT DISORDERS, 2021, 36 : S179 - S179
  • [8] Safety, tolerability and treatment effectiveness of chronic hepatitis B patients with pradefovir: a phase 1b multiple ascending dose study
    Jingrui, L.
    Junqi, N.
    Yanhua, D.
    Ning, X.
    Xiaoxue, Z.
    Xiaojiao, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S105 - S105
  • [9] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca W.
    Berg, Deborah
    Lin, Jianchang
    Fedyk, Eric Robert
    Palumbo, Antonio
    Stockerl-Goldstein, Keith E.
    BLOOD, 2019, 134
  • [10] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
    Gong, Jifang
    Guo, Ye
    Zhang, Yanqiao
    Ba, Yi
    Chen, Tong
    Li, Wei
    Zhou, Caicun
    Wang, Mengzhao
    Yang, Haiyan
    Zhou, Yuhong
    Cai, Qiqing
    Wang, Ziping
    Huang, Gang
    Zhang, Wei
    Su, Rila
    Cai, Zhongheng
    Yue, Zenglian
    Dou, Jinzhou
    Li, Peiqi
    Wu, Rachel
    Tse, Archie N.
    Shen, Lin
    TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
12345